Agenda

  • Dec
    2022

  • 06/12
    Eligo Bioscience: Powering the scale-up of its microbiome engineering platform
  • Mar
    2023

  • 14/03
    Bioprocessing Summit Europe 2023

News

Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress

17 November 2022

Alderaan Biotechnology ALD2510 antibody shows promising tolerability and efficacy results for treatment of gynecologic and breast cancers.

TO KNOW MORE

Pierre Fabre; Atara: CHMP Recommends Approval of Atara Biotherapeutics’ EbvalloTM (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

17 November 2022

Atara Biotherapeutics, Inc. and Pierre Fabre today announced the CHMP of the EMA has adopted a positive opinion recommending the EC approval of EbvalloTM (tabelecleucel) as a monotherapy for treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy.

TO KNOW MORE

subscribe to our newsletter

Our Board of Directors

Our members & Sponsors

This is a unique website which will require a more modern browser to work!

Please upgrade today!